8-K: Microbot Medical's LIBERTY System Adopted by Tampa General

Microbot Medical Inc. announced that Tampa General Hospital is the first health system in Florida to adopt its LIBERTY Endovascular Robotic System, following recent FDA clearance.

Summary

• Microbot Medical Inc. announced that Tampa General Hospital (TGH) has become the first health system in Florida to adopt the LIBERTY Endovascular Robotic System.
• This adoption follows the Company's recent FDA 510(k) clearance for the LIBERTY system.
• The U.S. market for peripheral endovascular procedures is approximately 2.5 million annually, representing a significant commercial opportunity.
• The LIBERTY system is the only FDA cleared, single-use, remotely operated robotic system designed for precise vascular navigation, aiming to reduce radiation exposure and physical strain for physicians.
• Microbot commenced a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating strong early commercial traction and validation for Microbot Medical's LIBERTY system following its FDA clearance. The partnership with a prominent institution like Tampa General Hospital is a significant endorsement.

Positives

• Tampa General Hospital is the first health system in Florida to adopt the LIBERTY Endovascular Robotic System, signaling early post-clearance momentum.
• The adoption by a nationally ranked research and academic medical center like TGH serves as a powerful endorsement of LIBERTY's differentiated value and market relevance.
• The LIBERTY system has the potential to transform care delivery, extend advanced innovation to patients, and protect the long-term health of physicians by addressing radiation safety and ergonomic strain.
• The U.S. market for peripheral endovascular procedures is substantial, with approximately 2.5 million procedures annually.
• Microbot's sales team is making further progress during the limited market release, with engagement across additional hospitals.

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Risks in the development of future versions of or applications for the system.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA.
• Announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

Microbot Medical plans to scale its commercial footprint ahead of the full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026. The company's sales team is actively engaging with additional hospitals during the limited market release, aiming to deepen market adoption.

Management Comments

• "As the first health system in Florida to adopt LIBERTY, we are advancing our commitment to leading-edge technology that has the potential to meaningfully transform how care is delivered." Dr. Jean Bismuth, Division Chief of Vascular Surgery for University of South Florida Morsani College of Medicine and Medical Director, TGH Heart & Vascular Institute.
• "LIBERTY brings sophisticated robotic capabilities to the endovascular space, allowing us to extend advanced innovation directly to our patients. It also has the potential to protect the long-term health of our physicians by addressing growing concerns around radiation safety and ergonomic strain." Dr. Jean Bismuth.
• "Endovascular robotics has the potential to level the playing field and significantly enhance our ability to navigate increasingly complex anatomy." Dr. Charles Briggs.
• "Tampa General Hospitals strong culture of innovation and clinical leadership makes them an ideal partner as the first health system in Florida to adopt LIBERTY. We believe that this serves as a powerful endorsement of LIBERTYs differentiated value and market relevance." Harel Gadot, CEO, President & Chairman.

Industry Context

StockSavvy.ai notes that the adoption of robotic systems in surgery, particularly in minimally invasive procedures like endovascular interventions, is a growing trend driven by the desire for increased precision, improved patient outcomes, and enhanced physician safety. This announcement positions Microbot Medical as an early mover in the endovascular robotics space, leveraging its recent FDA clearance to secure a significant partnership with a leading academic medical center. The focus on reducing radiation exposure and ergonomic strain for physicians aligns with broader industry efforts to improve the working conditions for medical professionals.

Comparison to Industry Standards

• The filing highlights LIBERTY as the "only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures." This differentiates it from multi-use or non-remotely operated systems.
• While specific comparable companies or projects are not named in the filing, the broader robotic surgery market includes players like Intuitive Surgical (da Vinci system for general surgery), Medtronic (Hugo RAS system), and Johnson & Johnson (Ottava system), which focus on various surgical specialties. LIBERTY's specific focus on peripheral endovascular procedures and its single-use, remotely operated nature positions it uniquely within this competitive landscape.
• Tampa General Hospital's ranking as the #1 hospital in Tampa Bay by U.S. News & World Report for 2025-26 and national ranking in six specialties suggests a high standard of care and a commitment to adopting advanced technologies, indicating a strong validation for LIBERTY.

Stakeholder Impact

• Shareholders: Positive impact due to significant product adoption, market validation, and potential for future revenue growth.
• Patients: Potential for improved care delivery, advanced innovation, and enhanced safety in endovascular procedures.
• Physicians: Potential for reduced radiation exposure and ergonomic strain, improving long-term health and enhancing ability to navigate complex anatomy.
• Hospitals/Healthcare Systems: Opportunity to adopt leading-edge technology, enhance clinical capabilities, and improve physician safety.

Next Steps

• Scale commercial footprint.
• Full market release at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepen market adoption.

Key Dates

Recommendation

The adoption of the LIBERTY system by a major academic medical center like Tampa General Hospital, especially as the first in Florida post-FDA clearance, represents a significant commercial milestone and strong market validation. This event signals early momentum in a large and growing market, potentially accelerating broader adoption and future revenue streams. The unique features of the system, addressing physician safety and procedural precision, provide a competitive advantage. This news is highly positive and suggests a strong growth trajectory for Microbot Medical.

Keywords

Endovascular Robotics, Medical Devices, LIBERTY System, Microbot Medical, FDA Clearance, Tampa General Hospital, Robotic Surgery, Peripheral Procedures, Healthcare Technology, MBOT